PDF Cover

Mirvetuximab Soravtansine Market

The market for Mirvetuximab Soravtansine was estimated at $361 million in 2024; it is anticipated to increase to $541 million by 2030, with projections indicating growth to around $759 million by 2035.

Report ID:DS1802203
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Mirvetuximab Soravtansine
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Mirvetuximab Soravtansine Market Outlook

Revenue, 2024

$361M

Forecast, 2034

$709M

CAGR, 2025 - 2034

7.0%

The Mirvetuximab Soravtansine industry revenue is expected to be around $385.9 million in 2025 and expected to showcase growth with 7.0% CAGR between 2025 and 2034. Further driving this growth trajectory is the expanding demand for Mirvetuximab Soravtansine in the medical field due to its proven effectiveness as an innovative therapeutic approach for the treatment of various cancers. The ongoing development of this revolutionary drug and its broad application base continue to solidify its relevance in the pharmaceutical industry. The drugs high efficacy in addressing hard-to-treat malignancies, coupled with advancements in oncological research, underscore its current significance. Meanwhile, the rise in the prevalence of cancer globally fuels this continuous demand, along with increasing health awareness and emphasis on early diagnosis.

The key attributes of Mirvetuximab Soravtansine revolve around its unique formulation that combines a-humanized anti-FR antibody with a potent anti-microtubule cytotoxic compound, thereby offering a targeted and efficient treatment method. Specifically engineered for patients with folate receptor alpha (FR)-positive cancer, this anticancer agent has shown promising results in diverse clinical trials. Furthermore, the recent trend of integrating personalized medicine into cancer therapy has amplified its demand.

Mirvetuximab Soravtansine market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Mirvetuximab Soravtansine Market Outlook

Market Key Insights

  • The Mirvetuximab Soravtansine market is projected to grow from $360.7 million in 2024 to $710 million in 2034. This represents a CAGR of 7%, reflecting rising demand across Ovarian Cancer Treatment, Folate Receptor Alpha Targeted Therapy, and Platinum-Resistant Cancer Treatment.

  • ImmunoGen Inc, Sanofi, Eli Lilly and Company are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Mirvetuximab Soravtansine market and are expected to observe the growth CAGR of 4.5% to 6.7% between 2024 and 2030.

  • Emerging markets including India, Brazil and South Korea are expected to observe highest growth with CAGR ranging between 8.0% to 9.7%.

  • Transition like Revamping Oncology Treatment has greater influence in U.S. and Germany market's value chain; and is expected to add $16 million of additional value to Mirvetuximab Soravtansine industry revenue by 2030.

  • The Mirvetuximab Soravtansine market is set to add $349 million between 2024 and 2034, with manufacturer targeting Speciality Clinics & Research Institutes Application projected to gain a larger market share.

  • With

    rising prevalence of ovarian cancer and growing adoption of targeted antibody-drug conjugates, and

    Advancements in biomarker-driven folate receptor alpha targeted therapy for personalized treatment, Mirvetuximab Soravtansine market to expand 97% between 2024 and 2034.

mirvetuximab soravtansine market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Mirvetuximab Soravtansine - Country Share Analysis

Opportunities in the Mirvetuximab Soravtansine

As the global population ages, the demand for effective cancer treatments continues to rise.

Growth Opportunities in North America and Europe

As a region characterized by its innovative healthcare facilities and emerging biotechnology firms, North America presents a favorable market strand for Mirvetuximab Soravtansine. The application of this antibody-drug conjugate in treating ovarian cancer reveals significant value, considering the increasing incidence rate in this region. Strong competitive pressure exists, driven primarily by rival firms thriving in the biopharma domain, adding a layer of complexity to the market. Nevertheless, the regions robust healthcare infrastructure, coupled with the high incidence of ovarian cancer, forms key market drivers. The stimulants that support the use of Mirvetuximab Soravtansine touch on technological advancements in cancer therapeutics and the push for targeted drug delivery systems.
Europe's market for Mirvetuximab Soravtansine is buoyed by its advanced medical research capabilities and the burgeoning investments in cancer research. It goes hand in hand with the rise in ovarian cancer cases across the region. Competitively, Europe's market is stratified, with intense competition from seasoned pharma players and new entrants, making market penetration challenging. Despite this, the regions command on leading-edge medical research and the consistent demand generated by the high ovarian cancer prevalence work as significant market propellants.

Market Dynamics and Supply Chain

01

Driver: Rising prevalence of ovarian cancer and growing adoption of targeted antibody-drug conjugates

The increasing incidence of ovarian cancer, particularly among aging populations, is also a major driver for the mirvetuximab soravtansine market. Enhanced diagnostic awareness, improved screening techniques, and earlier detection of epithelial ovarian cancer are also identifying more patients eligible for targeted therapy, directly expanding the addressable population. Separately, the growing adoption of antibody-drug conjugates (ADCs) in oncology is also fueling demand, as these therapies combine the specificity of monoclonal antibodies with potent cytotoxic agents to improve efficacy while minimizing systemic toxicity. Clinicians are also increasingly favoring ADCs for patients with high folate receptor alpha expression, where conventional chemotherapy often fails. Together, the rise in ovarian cancer prevalence and the shift toward precision ADC therapies are also reshaping treatment paradigms, stimulating investment in clinical trials, regulatory approvals, and commercialization strategies for mirvetuximab soravtansine across specialty oncology practices.
A key driver for mirvetuximab soravtansine is also the development of biomarker-guided therapies targeting folate receptor alpha (FRα). Companion diagnostic tests now allow oncologists to identify patients whose tumors overexpress FRα, enabling personalized treatment selection and improved response rates. This precision medicine approach enhances clinical outcomes by delivering cytotoxic payloads specifically to malignant cells, reducing off-target effects compared with conventional chemotherapy. The trend toward FRα-targeted, biomarker-driven therapy reflects broader also advances in oncology, including molecular profiling and precision therapeutics, positioning mirvetuximab soravtansine as a niche but high-impact option in targeted ovarian cancer treatment.
02

Restraint: High treatment cost and reimbursement challenges limit patient access and uptake

One of the most significant restraints for mirvetuximab soravtansine is its high therapy cost and inconsistent reimbursement coverage across healthcare systems. Due to complex manufacturing processes and stringent regulatory requirements for antibody‑drug conjugates, pricing remains elevated, posing affordability challenges for many patients. Health technology assessments have found that at current prices, mirvetuximab soravtansine may not be cost‑effective compared with standard chemotherapy in some markets, limiting payer willingness to fund treatment. This pricing barrier reduces patient access, particularly in resource‑constrained regions where out‑of‑pocket expenses are prohibitive, dampening overall demand and revenue growth.
03

Opportunity: Technological Innovations and Strategic Collaborations and Exploring Untapped Segments

The coming years are anticipated to witness substantial technological advancements in the pharmaceuticals sector. Enhancing the efficacy and reducing the potential side effects of medications like Mirvetuximab Soravtansine through innovations may revolutionize the treatment landscape. Moreover, strategic collaborations and partnerships with other leading pharmaceutical firms, research institutions, and biotech startups can help speed up the development and market penetration process for Mirvetuximab Soravtansine.
The oncology arena is undergoing a paradigm shift, as novel therapeutic methods such as Mirvetuximab Soravtansine gain momentum. The potential of Mirvetuximab Soravtansine in treating other tumors and cancers remains largely untapped, posing a robust for business growth. By demonstrating potential effectiveness across a more extensive range of cancers, including off-label use, the market scope for Mirvetuximab Soravtansine can significantly broaden.
04

Challenge: Limited eligible patient population and diagnostic testing barriers restrict broader adoption

Mirvetuximab soravtansine’s use is restricted to patients with high folate receptor alpha expression, requiring specific diagnostic testing to determine eligibility. FRα testing is not yet standard practice in all oncology settings, creating barriers to patient identification and delaying treatment initiation. Additionally, limited access to companion diagnostic assays and associated costs can deter clinicians from routine testing, narrowing the treatable population. Because only a subset of platinum‑resistant ovarian cancer patients qualify for therapy, the market remains focused on a niche segment, constraining expansion and broader adoption across oncology practices.

Supply Chain Landscape

1

Raw Material Acquisition

Latitude PharmaceuticalsSymbiotec Pharmalab
2

Drug Development

ImmunoGenSanofi
3

Clinical Research

CHDRClinical Research Services
4

Distribution

Ovarian Cancer ChemotherapyHER2 Negative Breast Cancer Treatment
Mirvetuximab Soravtansine - Supply Chain

Use Cases of Mirvetuximab Soravtansine in Ovarian Cancer Treatment & Platinum-Resistant Cancer Treatment

Ovarian Cancer Treatment : In ovarian cancer treatment, mirvetuximab soravtansine is primarily used as an intravenous antibody‑drug conjugate that targets folate receptor alpha on tumor cells, particularly in platinum‑resistant epithelial ovarian cancer patients who have received one to three prior systemic therapies. This targeted therapy combines an FRα‑binding antibody with a cytotoxic maytansinoid payload, allowing selective internalization and tumor cell death. It has demonstrated clinically meaningful objective response rates and improved progression‑free survival in patients with high FRα expression, offering a valuable option where traditional chemotherapies often fail.
Folate Receptor Alpha Targeted Therapy : As a folate receptor alpha targeted therapy, mirvetuximab soravtansine serves the needs of patients whose tumors overexpress FRα, a biomarker found in a high percentage of ovarian cancers and some other gynecologic malignancies. Oncologists use companion diagnostic tests to identify eligible patients who are most likely to respond to this precision medicine approach. The targeted mechanism delivers cytotoxic agents directly into malignant cells, improving efficacy while reducing off‑target toxicity compared with conventional therapies. This precision oncology strategy exemplifies advances in biomarker‑driven cancer treatment.
Platinum-Resistant Cancer Treatment : In the treatment of platinum‑resistant cancer, mirvetuximab soravtansine is used when tumors no longer respond to standard platinum‑based chemotherapy, a common challenge in advanced ovarian, fallopian tube, or primary peritoneal cancers. As an innovative antibody–drug conjugate, it provides a new line of therapy for patients with limited options, showing meaningful responses and manageable safety profiles in clinical trials. By addressing resistance mechanisms with targeted cytotoxic delivery, it fills a critical gap in current oncology treatment paradigms.

Recent Developments

Recent developments for mirvetuximab soravtansine highlight its growing role in precision oncology and targeted therapy for folate receptor alpha positive cancers, particularly platinum‑resistant ovarian cancer. A key market trend is integration of companion diagnostic testing to identify eligible patients, boosting biomarker‑driven treatment adoption. Enhanced clinical evidence showing improved response rates and progression‑free survival is strengthening uptake among oncologists. Broader use of antibody‑drug conjugates in personalized cancer care continues to shape competitive dynamics and therapeutic strategies.

December 2024 : Roche announced a strategic partnership with ImmunoGen to further the development of Mirvetuximab Soravtansine, enhancing its portfolio in oncology drugs
October 2024 : FDA granted accelerated approval for Mirvetuximab Soravtansine, by ImmunoGen for the treatment of certains of ovarian cancer
August 2024 : ImmunoGen revealed pivotal phase 3 trial data for Mirvetuximab Soravtansine, demonstrating significant improvements in progression-free survival rates.

Impact of Industry Transitions on the Mirvetuximab Soravtansine Market

As a core segment of the Pharmaceutical industry, the Mirvetuximab Soravtansine market develops in line with broader industry shifts. Over recent years, transitions such as Revamping Oncology Treatment and Driving Personalized Medicine have redefined priorities across the Pharmaceutical sector, influencing how the Mirvetuximab Soravtansine market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Revamping Oncology Treatment

Mirvetuximab Soravtansine, an immunotherapy drug, has been a significant transition in the oncology sector. Its prowess lies in its ability to target specific cancer cells, notably ovarian cancer, while leaving healthy cells largely intact. The use of Mirvetuximab Soravtansine has resulted in a more personalized and efficient treatment protocol, further propelling the growth of targeted therapies and immunooncology. This transition has impacted the entire spectrum of cancer treatment, encouraging continuous research and innovation.
02

Driving Personalized Medicine

The development of mirvetuximab soravtansine has significantly advanced the field of personalized medicine, exemplifying how therapies can be tailored to individual genetic profiles. By specifically targeting folate receptor alpha, which is frequently overexpressed in ovarian cancer, the drug allows clinicians to select patients most likely to respond, optimizing treatment efficacy while minimizing off-target toxicity. This precision approach is influencing associated industries, including companion diagnostic developers, oncology laboratories, and clinical trial organizations, which are increasingly integrating biomarker testing into their workflows. Pharmaceutical companies are also investing in targeted antibody-drug conjugates, reflecting a broader shift toward precision oncology, biomarker-driven therapy approvals, and evidence-based treatment paradigms across specialty cancer care.